Deutsche Bank upgraded shares of Calpine (NYSE:CPN) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Calpine Corp. (NYSE:CPN) in last trading activity fell -0.81% to close at $22.13. Company weekly performance is 2.50% while its quarterly performance stands at 1.47%. Calpine Corp. (NYSE:CPN) is -9.19% away from its 52 week high.
Maxim Integrated Products (NASDAQ:MXIM) CEO Tunc Doluca sold 9,600 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $32.00, for a total transaction of $307,200.00. Following the sale, the chief executive officer now directly owns 76,000 shares in the company, valued at approximately $2,432,000. On last trading day Maxim Integrated Products, Inc. (NASDAQ:MXIM) increased 1.97% to close at $31.87. Its volatility for the week is 1.78% while volatility for the month is 2.12%. MXIM’s sales growth for past 5 years was 8.30% and its EPS growth for past 5 years was 110.20%. Maxim Integrated Products, Inc. (NASDAQ:MXIM) monthly performance is 9.37%.
Athersys, Inc. (NASDAQ:ATHX) announced the completion of patient enrollment process for a phase II study on its MultiStem cell therapy. The randomized, double-blind, placebo-controlled, multi-center study is evaluating the safety and efficacy of MultiStem therapy in patients suffering from moderate to moderate-severe ischemic strokes. Athersys, Inc. (NASDAQ:ATHX) has 3.60% insider ownership while its institutional ownership stands at 29.10%. In last trading activity company’s stock closed at $1.58.
Sandler O’Neill initiated coverage on shares of Hudson Pacific Properties (NYSE:HPP) in a research report sent to investors on Tuesday morning. The firm issued a buy rating on the stock. On Wednesday shares of Hudson Pacific Properties, Inc. (NYSE:HPP) closed at $30.06. Company’s sales growth for last 5 years was 34.30% and EPS growth for next 5 years is recorded as 12.23%.
BioMarin Pharmaceutical (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 5,000 shares of the stock on the open market in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $88.73, for a total value of $443,650.00. Following the completion of the sale, the chief executive officer now directly owns 227,157 shares of the company’s stock, valued at approximately $20,155,641. On last trading day BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) increased 0.07% to close at $90.40. Its volatility for the week is 3.18% while volatility for the month is 3.82%. BMRN’s sales growth for past 5 years was 13.10% and its EPS growth for past 5 years was -44.30%. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) monthly performance is 0.27%.